MTOR and lymphangiomyoma: They encompass angiomyolipomas, lymphangioleiomyomas, and related tumors, many of which share pathogenic activation of the mammalian target of rapamycin (mTOR) signaling pathway, particularly in association with tuberous sclerosis complex (TSC) [1].